Pain management practices use TITN for TM-Flow autonomic, sudomotor, and vascular testing, ordered when clinically indicated and captured chairside in about ten minutes. ALTMS adds FDA-cleared rTMS for adults with diagnosed major depressive disorder who have not improved on prior antidepressant medication; it treats the depression, not the pain.
Because complex pain presentations often leave the chart without measured findings. TM-Flow records heart rate variability, sudomotor response from galvanic skin response, and ankle-brachial indices as documented indices in one chairside visit. Autonomic testing is a recognized adjunct in the small fiber neuropathy workup. Your clinician interprets every value; the system does not diagnose.
TM-Flow captures heart rate variability, sudomotor function, ankle-brachial indices, and arterial stiffness in one ten-minute chairside test, ordered when clinically indicated and documented for the record.
Autonomic and sudomotor findings sit alongside history, exam, and where indicated skin biopsy. A normal autonomic result does not rule out small fiber neuropathy, and an abnormal one is one input, not a diagnosis.
For adults with diagnosed major depressive disorder in the caseload who have not improved on prior antidepressant medication, ALTMS delivers FDA-cleared rTMS (K220625) as a course of care. The clearance covers major depressive disorder only. It treats the depression, not the pain.
TM-Flow is the measurement layer: three FDA 510(k)-cleared modules (K173696, K152216, K200141) covering autonomic function, sudomotor response, and ankle-brachial index, with coverage decided by your payer. ALTMS is FDA-cleared rTMS (K220625) for adults with major depressive disorder who have not improved on prior antidepressant medication. The Hue Light BAHI suite is positioned under FDA General Wellness, not FDA cleared, and is cash pay.
Autonomic function, sudomotor, and ankle-brachial testing in one visit, measuring HRV, sudomotor response, and ABI. TM-Flow System, built on three FDA 510(k)-cleared modules (K173696, K152216, K200141).
ALTMS is FDA-cleared for adults with major depressive disorder who have not improved on prior antidepressant medication. In a pain management practice, patients with diagnosed MDD are a clinical target in their own right. ALTMS addresses the depression, not the pain itself. The Hue Light BAHI suite adds a recovery layer alongside the care plan.
FDA-cleared rTMS therapy for adults with major depressive disorder who have not improved on prior antidepressant medication. The MDD that often travels with chronic pain is its own clinical indication; ALTMS targets that comorbidity, not the pain itself.
Photobiomodulation, molecular hydrogen, pressurized oxygen, and whole-body vibration. A recovery and wellness layer alongside the care plan.
The reason clinics keep the equipment running is the wrap around it. Here is what comes with a pain management placement, and how we build the practice around it.
Live sessions, recorded walkthroughs, and interpretation guides. Your team runs real tests; a TITN clinical trainer reviews the reports with them until interpretation sticks.
The coverage checklist per device, your contractor's policy read with you, documentation templates, and your certified coder in the loop.
On-site or remote setup, calibration, and staff onboarding. A named TITN contact, not a ticket queue.
Flexible financing structures designed around your expected reimbursement timing. Multiple lender and lease pathways with transparent ROI modeling.
Workflow design, reimbursement coaching, protocol setup. Practical, billable advice.
Mobile-first WordPress sites with scheduling baked in. The same aesthetic as this one.
AI-generated brand films or full productions filmed at your clinic. Edited, scored, finished.
Local SEO, structured data, and CRM lead-intake that routes new-patient inquiries automatically.
The questions a pain practice asks before it orders anything.
TM-Flow for autonomic, sudomotor, and vascular testing, built on three FDA 510(k)-cleared modules (K173696, K152216, K200141) and run chairside in about ten minutes. It records heart rate variability, galvanic skin response, ankle-brachial indices, and the manufacturer's derived arterial stiffness indices as measured values documented for the record. Ordered when clinically indicated, never routinely on every patient.
TM-Flow coverage and coding are set by each Medicare contractor and commercial plan on the documented indication, and California's contractor publishes no autonomic policy. TITN recommends no code; your contractor and plan decide, and your own certified coder should confirm anything before you bill it. Autonomic function testing also carries documented subject-preparation, environment, and trained-personnel requirements in Medicare coding guidance.
Yes, as an adjunct. Autonomic testing, including sudomotor and cardiovagal measures, is a recognized part of the workup for suspected small fiber neuropathy alongside clinical history, exam, and skin biopsy for intraepidermal nerve fiber density. TM-Flow documents those measured indices in one visit. It is not a replacement for biopsy-confirmed diagnosis, and the literature notes that some autonomic tests are time- and resource-intensive.
No. Diagnosis rests primarily on history and clinical examination, with functional testing and skin biopsy used for confirmation. A normal autonomic result does not exclude small fiber neuropathy on its own, and it should not close the workup. Read TM-Flow indices as one documented data point the treating clinician weighs against the rest of the picture.
Reported sensitivity and specificity vary by study and by test site, with feet and hands performing differently, and results are strongest when the test is paired with an established screening instrument rather than used alone. TM-Flow's sudomotor module (K152216) measures galvanic skin response related to sweat-gland function. Treat the value as a measured index your clinician interprets, not a standalone accuracy claim.
ALTMS is FDA cleared (K220625) for adults with major depressive disorder who have not improved on prior antidepressant medication in the current episode. That clearance does not extend to pain. Pain-specific rTMS indications are a separate and less established evidence question, and nothing on this page should be read as a pain claim. In a pain practice, ALTMS treats the diagnosed depression, not the pain.
The treating clinician screens every patient against the manufacturer's contraindications, which include implanted devices in or near the head, epilepsy or a history of seizures, and pregnancy, per the REMED instructions for use, section 1.4. rTMS carries a known risk of seizure. Conductive or ferromagnetic metal near the coil, such as cochlear implants, deep brain stimulators, aneurysm clips, and stents, is the core exclusion.
TM-Flow results return on TITN's HIPAA-compliant portal and can come back interpreted through BMTG rather than as a raw tracing, so your team gets a read. Reports are prepared by outside credentialed reviewers, and board-certified neurologists sign the BMTG reads on autonomic data. Nothing here implies an in-house sign-off; the ordering provider remains the patient's point of care.
A short call covers devices, reimbursement, and onboarding for your workflow. No commitment beyond the first conversation.
Roberto or Weston takes the call personally. We walk you through TM-Flow, ALTMS, Hue Light BAHI, and the billing path for pain management.
Pick a time →A de-identified, watermarked sample of the autonomic report your practice would receive from a TM-Flow workup.
Open the sample →FDA 510(k) clearances verified in the openFDA device database. Coverage policies are read in the CMS Medicare Coverage Database. Coverage and payment are decided by each payer on the documented indication; nothing on this site is a guarantee of payment.